Cybin Inc (HELP)

• Market cap: $201M
• 1 day: -3.13%
• 5 days: -14.83%
• 1 month: -24.29%
• 3 months: -27.17%
• 6 months: -31.98%
• Year to date: -51.45%
• 1 year: -52.43%
• 5 years: -96.17%
• 10 years: -96.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Employees: 50